Business Context and Reporting Period
This Form 8-K Current Report was filed by Enochian Biosciences, Inc. on July 18, 2018. The registrant is incorporated in Delaware and maintains its principal executive offices in Los Angeles, California. The filing reports a corporate governance event rather than financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. Item 9.01 explicitly states that financial statements are "Not applicable" for this report.
Material Changes
There are no material financial changes reported. The sole material event disclosed is the appointment of David Hardy, MD to the company's Scientific Advisory Board, announced via press release on July 18, 2018.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, specific risks, contingencies, or unusual items. The document serves solely to disclose the advisory board appointment.
Investor Verification Checklist
- Verify the identity and credentials of the newly appointed Scientific Advisory Board member, David Hardy, MD.
- Review the attached press release (Exhibit 99.1) for details on the scope of the new appointment.
- Confirm that no other undisclosed events occurred during the reporting period.
- Note that this filing does not contain updated financial data; refer to the most recent 10-K or 10-Q for financial status.